Big news! NBDF’s Pathway to Cures portfolio company Spark Biomedical was selected by Wellcome Leap as an awardee of “The Missed Vital Sign” worldwide program. The goal of the program is to demonstrate that routine recording quantifiable measurement, and better treatment options for menstruation can reduce the time it takes a woman to get effective treatment for heavy menstrual bleeding from 5 years to 5 months.
The Wellcome Leap team reminds us that, “Every minute, somewhere in the US, a woman requires a blood transfusion because of her menstruation. Heavy menstrual bleeding (HMB) often involves blood loss so significant that if it was associated with an injury, it would result in a call for an ambulance or a trip to the emergency room. HMB is reported by 1 in 3 women and is more common than asthma or diabetes in reproductive aged women.”
NBDF’s Pathway to Cures supports innovative companies addressing unmet needs in our community through investment and more. Congratulations to Spark Biomedical and awardee Dr. Navid Khodaparast, co-founder and CSO of Spark Biomedical.
Spark Biomedical can be found at booth 329 featuring its wellness product Ohmbody and recently provided an overview of the science of their approach at an NBDF Wednesday Webinar.
Pathway to Cures is the venture philanthropy fund of the National Bleeding Disorders Foundation.
Paid Advertisement.
NBDF does not endorse products or manufacturers.